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Respiratory syncytial virus (RSV) is one of the 
most common causes of viral bronchiolitis and 
a major cause for hospitalization in infants, el-
derly and high risk adults (1). RSV infection is 
characterized by epithelial cell necrosis, a lym-
phocytic infi  ltrate in the lung and edema lead-
ing to obstruction of the smaller airways by 
cellular debris and mucus (2). In addition to the 
acute eff  ects of RSV infection on the immune 
system, RSV also causes long-term changes in 
the immunological environment in the lung. 
This is of particular concern in light of the ob-
servation that RSV infection in early infancy 
was correlated with development of allergic 
and asthmatic symptoms later in life (3). How-
ever, the immune response to RSV is still com-
plex and puzzling. Infection with RSV leads to 
poor development of immunity and recurrent 
infections are common, exemplifi  ed by the 
failure of an RSV vaccine in the 1960s (4). 
Therefore, a better understanding of the im-
munological responses elicited during RSV in-
fection may contribute to the development of 
new treatment strategies or novel vaccines.
Murine models of RSV infection have been 
eff  ectively used to study innate and acquired 
immune responses. RSV infection of BALB/c 
mice elicits a vigorous infl  ammatory response 
in the lung leading to airway hyperresponsive-
ness, CD4+ and CD8+ T cell infl  ux, and in-
creased production of mucus (5, 6). Crucial 
in the elicitation of acquired immune responses 
in the lung is the DC. During priming of the 
immune response in the lung, immature pul-
monary DCs internalize antigens, mature, and 
emigrate the tissue to the local lymph nodes 
where they present the antigen to naive T cells 
(7). In addition, during ongoing infl  ammation, 
DCs migrate into the tissue where they main-
tain and enhance local immune responses (8). 
In humans and mice, several subtypes of DCs 
have been described, as characterized by sur-
face markers and function. Generally, DCs can 
be distinguished into conventional DCs (cDC 
or “myeloid” DCs) and plasmacytoid DCs 
(pDCs) (9).
Not much is known about the role of dif-
ferent subsets of DCs in respiratory viral infec-
tions. After infl  uenza A virus infection of mice, 
a strong increase in both immature and mature 
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DCs was observed in the lung (10), whereas an increase of 
CD11b−/CD8α− DCs, most likely pDCs, was observed in 
the mediastinal lymph nodes of mice after infl  uenza A infec-
tion (11). In a mouse RSV infection model, it was demon-
strated that RSV caused a persistent increase in pulmonary 
DCs, which displayed a mature phenotype (12). The diff  erent 
subtypes of DCs were not distinguished in the latter studies. 
Interestingly, a recent study showed that both cDC and pDC 
numbers were increased in nasal washings of RSV-  infected 
infants (13). However, so far, nothing is known about the 
contribution of diff  erent DC subtypes to the immunopathol-
ogy in RSV infection. Therefore, in this study, we investi-
gated the eff  ect of RSV infection on cDC and pDC numbers 
in the lung and lung-draining lymph nodes. Moreover, we 
investigated the functional role of pDCs in RSV-mediated 
lung immunopathology and in RSV viral clearance.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
The number of cDCs and pDCs are increased in lungs 
of RSV-infected mice
To investigate the number of cDCs and pDCs after RSV in-
fection, lungs and lung-draining lymph nodes of mice were 
analyzed at diff  erent time points after infection for the pres-
ence of CD11chigh/CD11bhigh cDCs or CD11c+/B220+, 
CD11c+/mPDCA1+, and CD11c+/120G8+ pDCs (Fig. 1 
and Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20052359/DC1). During RSV infection, the num-
ber of both cDCs and pDCs increased signifi  cantly. Interest-
ingly, the increase in the number of pDCs in the lung was 
sustained until 30 days post-infection (dpi) when infected 
lungs still contained signifi  cantly more pDCs compared with 
naive mice. In the lymph nodes, both cDC and pDC num-
bers showed a temporary peak at 7 dpi. These data show that 
both cDC and pDC cell numbers are increased consider-
ably in both lungs and lung-draining lymph nodes after RSV 
infection. However, only the increase in pDCs in the lung 
was sustained until 30 dpi.
These data suggest that the sustained number of CD11c+/
MHChigh DCs, observed in studies in mice by Beyer et al. in 
the lung after RSV infection, may be pDCs (12). In line with 
these and our results is a recent study that showed that both 
cDC and pDC numbers were increased signifi  cantly in nasal 
washings of RSV-infected children (13). In this study, it was 
also observed that the number of pDCs was still increased af-
ter apparent resolution of RSV infection. Collectively, these 
data support the hypothesis that recruitment of recently at-
tracted DCs in the lung leads to maintenance and control of 
the immune response in the lung as suggested by van Rijt 
et al. (8), even after the actual infection and infl  ammation in 
the lung is resolved. In addition, the sustained presence of 
pDCs in the lung after apparent resolution of RSV infection 
may also suggest that RSV infection of BALB/c mice can 
become either latent or persistent, as suggested by studies 
both in mice (14) and infants (15). So far, nobody has de-
scribed the role of pDCs in respiratory viral infections in 
vivo.   Previously, others have suggested that pDCs in the lung 
have tolerogenic functions after pulmonary allergen expo-
sure, by inhibition of T eff  ector cell induction or indirectly 
by induction of regulatory T cells in the lung-draining lymph 
nodes (16–18).
The 120G8 antibody effectively depletes pDCs in the lung
Unfortunately, selective targeting of cDCs is still impossible 
because of the surface markers it shares with other immune 
Figure 1.  Numbers of cDCs and pDCs in the lung and the lung-
draining lymph nodes are increased upon RSV infection. Before and 
at different time points after RSV (■) or uvRSV (▲) infection, single cell 
suspensions of lungs and lung-draining lymph nodes were analyzed by 
fl  ow cytometry for the presence of cDCs (CD11chigh/CD11bhigh) and pDCs 
(CD11c+/B220+). Results are displayed as percentage of lung cells (A), 
total number of cells per lung (B), percentage of lymph node cells (C), or 
total number of cells per lymph node (D) ± SEM. *, P < 0.05 compared 
with noninfected control mice, n = 4–7 mice per group.JEM VOL. 203, May 15, 2006  1155
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cells. However, depletion of pDCs has been performed 
in studies before, using anti-Gr-1, 120G8, 440c, or anti–
  mPDCA-1 antibodies (for review see reference 19), includ-
ing selective depletion in the lung (17). Therefore, in the 
next series of experiments, mice received the 120G8 anti-
body 1 d before and after RSV infection. The 120G8 anti-
body eff  ectively decreased the number of pDCs in lungs of 
RSV-infected mice, as demonstrated by a signifi  cant decrease 
in the number of CD11c/B220, CD11c/mPDCA1, and 
CD11c/Gr-1 double-positive cells on 1 dpi and 6 dpi (Table 
S1, available at http://www.jem.org/cgi/content/full/jem.
20052359/DC1). In contrast, the number of cDCs (CD11c/
CD11b double-positive cells) was not decreased in the lungs 
of RSV-infected mice after treatment with the 120G8 anti-
body. In addition, no eff  ect of pDC depletion was seen on 
the number of CD4+, CD8+ T cells, DX5+ NK cells, or 
CD19+ B cells on 1 dpi (unpublished data). These data show 
that the pDC depletion was selective in our model and eff  ec-
tively prevents the infl  ux of pDCs during RSV infection.
Depletion of pDCs enhances RSV-induced 
immunopathology in the lung
This study next investigated whether pDCs infl  uence mani-
festations of RSV-induced immunopathology in the lung. 
RSV-infected mice developed airway hyperreactivity, as 
measured by a strong increase in airway resistance in response 
to methacholine compared with control mice on 9 dpi (Fig. 
2 A). Depletion of pDCs around the time of RSV infection 
enhanced this airway hyperreactivity signifi  cantly. Histologi-
cal examination of control mice showed that RSV infection 
leads to a peribronchial and perivascular infl  ammatory infi  l-
trate consisting of mononuclear cells, mostly lymphocytes, 
and leads to goblet cell hyperplasia and mucus production in 
the lung (Fig. 2 B and Fig. S2, available at http://www.jem.
org/cgi/content/full/jem.20052359/DC1). Lungs of pDC-
depleted mice showed enhanced infl  ammation and mucus 
production. In addition, RSV infection elicited transcription 
of the mucus genes GOB-5 and Muc5ac, which was signifi  -
cantly increased in pDC-depleted mice (Fig. S2).
The aforementioned eff  ect of altered immunopathology 
in pDC-depleted mice may be the result of either an inability 
to clear virus properly, leading to an increased load of RSV 
virus, and/or immune deviation leading to enhanced T cell–
mediated responses. To determine whether pDCs play a role 
in clearance of RSV from the lung, RSV viral titers from 
lungs were measured by plaque assay and by viral G protein 
mRNA assay on 6 dpi (Fig. 2 C). Plasmacytoid DC depletion 
of RSV-infected mice signifi  cantly enhanced both viral titers 
and RSV G protein RNA levels in the lung. This  demonstrates 
Figure 2.  Depletion of pDCs enhances RSV-induced airway hyper-
responsiveness, infl  ammation, and mucus production in the lung 
and decreases clearance of RSV. (A) On 9 dpi, airway responses were 
measured in control (cont), RSV-infected (RSV), and pDC-depleted, RSV-
infected (RSV+120G8) mice after one dose of methacholine and com-
pared with basal measurements. Data are represented as mean airway 
resistance in cm H2O/ml/s ± SEM. *, P < 0.01 compared with noninfected 
control mice; #, P < 0.05 compared with RSV infected mice, n = 5 mice 
per group. (B) Lungs were isolated on 9 dpi and processed and sections 
were stained with H&E and PAS. Shown are representative lung sections 
of control (cont), RSV-infected (RSV), and pDC-depleted, RSV-infected 
(RSV+120G8) mice. Bars, 300 μM (H&E) and 75 μM (PAS). (C) On 6 dpi, 
RSV titers were determined in the lungs of RSV-infected (RSV) or pDC-
depleted, RSV-infected (RSV+120G8) mice by plaque assay. Data are pre-
sented as mean PFU per gram lung ± SEM, n = 4. *, P < 0.05 compared 
with RSV-infected mice, n = 5 mice. In addition, RSV G protein RNA 
  transcription in the lung on 6 dpi was measured by quantitative real-time 
PCR (Taqman). Data are represented as mean fold increase to RSV-
 infected  mice  ± SEM. *, P < 0.05 compared with RSV-infected mice, 
n = 5 mice per group.1156  PLASMACYTOID DENDRITIC CELLS IN RSV INFECTION | Smit et al. 
that pDCs enhance viral clearance during RSV infection. 
However, pDC depletion enhanced viral titers approximately 
twofold, indicating that the observed increase in pathology 
may not be the result of increased viral titer only.
Next, we investigated whether depletion of pDCs in the 
lung had an eff  ect on the cytokine environment induced by 
RSV. RSV infection enhanced production of both the Th1 
cytokine IFNγ and the Th2-type cytokines, IL-4, IL-5, and 
IL-13, by lymph node T cells after anti-CD3 restimulation 
compared with naive mice (Fig. 3 A). Depletion of pDCs 
signifi  cantly increased the production of all these cytokines. 
In addition, real-time PCR analysis showed that RSV infec-
tion elicited transcription of all of these cytokines in the lung 
(Fig. 3 B). Again, depletion of pDCs signifi  cantly enhanced 
the transcription of these cytokines. There are two compati-
ble possibilities to explain these data. First, pDCs in the lung 
or lung-draining lymph nodes may suppress the generation of 
eff  ector T cells as show by de Heer et al. after allergen expo-
sure in the lung (17). This may lead to the observed increased 
T cell responses after pDC depletion. Second, IFNα, pro-
duced mainly by pDCs, may enhance the cell-mediated anti-
viral immune response, allowing more effi   cient clearance of 
the virus. In this way, pDC depletion may lead to an in-
creased viral load after viral infection, which may lead to the 
enhanced immune responses observed.
To address the latter possibility, we investigated the di-
rect role of IFNα during RSV infection in control and 
pDC-depleted mice. After RSV infection, levels of both 
IFNα4 mRNA and IFNα protein in the lung were elevated 
signifi  cantly at 1 dpi followed by a decrease during viral rep-
lication at dpi 4, and an increase again during clearance of 
the virus at 7 dpi (Fig. 4 A). Depletion of pDCs by 120G8 
(Fig. 4 A) completely abolished transcription and production 
of IFNα throughout RSV infection. The diminished IFNα 
production in the lung after pDC depletion is in line with 
earlier reports that showed that pDCs are the primary pro-
ducers of IFNα during viral infection (20). Classically, IFNα 
generates a general antiviral environment by activation of 
NK cells and CD8+ T cells that both mediate lysis of in-
fected cells. In addition, IFNα together with IL-6 enhances 
the diff  erentiation of B cells into antibody-producing plasma 
cells (21). In mouse models of RSV infection, the protective 
role of IFNα was suggested by the observation that RSV in-
fection was exacerbated in STAT1 and IFNαβγR knockout 
mice (22, 23). For this reason, we investigated whether local 
administration of IFNα would modify the immune response 
after RSV infection. As shown in Fig. 4 B, IFNα signifi  -
cantly enhanced the clearance of RSV in both control and 
pDC-depleted mice. This confi  rms earlier reports in which 
administration of IFNα, or poly-IC, a potent IFNα inducer 
in vivo, decreased RSV titers and disease scores (24). In con-
trast, in our experiments, IFNα administration did not 
change airway hyperreactivity (Fig. 4 C) and lung lymph 
node T cell responses (Fig. 4 D) after RSV infection. More-
over, IFNα had no eff  ect on the elevated responses in pDC-
depleted mice.
Figure 3.  Depletion of pDCs enhances RSV-induced immunological 
responses in the lung. (A) Cytokine production of lymph node T cells 
in response to anti-CD3 stimulation. On 6 dpi, lung lymph nodes were 
isolated from control (Cont), RSV-infected (RSV), and pDC-depleted RSV-
infected (RSV +120G8) mice and stimulated with anti-CD3 at a concen-
tration of 5 × 106 cells/ml. Supernatants were analyzed using ELISA. Data 
are represented as mean ng/ml ± SEM. *, P < 0.01 compared with nonin-
fected control mice, #, P < 0.05 compared with RSV-infected mice, n = 4 
mice per group. (B) Messenger RNA levels of cytokines and chemokines 
in the lungs of mice. On 6 dpi, mRNA was isolated from lungs from con-
trol (Cont), RSV-infected (RSV), and pDC-depleted, RSV-infected (RSV 
+120G8) mice and analyzed using quantitative real-time PCR by Taqman. 
Each sample was normalized using a GAPDH control and the fi  gure shows 
mean fold increase to control ± SEM. *, P < 0.05 compared with nonin-
fected control mice; #, P < 0.05 compared with RSV-infected mice, 
n = 5–6 mice per group.JEM VOL. 203, May 15, 2006  1157
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These data would suggest that IFNα, secreted by pDCs, 
helps to clear RSV but does not change the adaptive immune 
response and airway hyperreactivity induced later in the 
course of RSV infection. This suggests that pDCs, next to 
playing a direct antiviral role by secreting IFNα, play a mod-
ulatory role in establishing T cell–mediated responses to 
pathogens in the lung as well. Although our experiments 
have not determined the direct mechanism of pDC function 
in this regard, we hypothesize that depletion of pDCs initially 
leads to increased viral antigen presentation by the immuno-
stimulatory cDC population. The enhanced T cell cytokine 
response would likely lead to the increased pathophysiology 
observed in the absence of pDCs, especially as it relates to the 
increased mucus overexpression and airway hyperreactivity.
In summary, this study demonstrated that RSV infection 
of mice caused a sustained increase in the number of pDCs in 
the lung. Plasmacytoid DCs play a substantial protective role 
during RSV infection because depletion of pDCs exacer-
bated all the measured parameters of RSV-induced airway 
disease. This protective eff  ect of pDCs is only partially medi-
ated through IFNα, as treatment with IFN-α correlated with 
enhanced clearance of RSV, but had little eff  ect on the de-
velopment of immune responses in the presence or absence 
of pDCs. Possibly, pDCs provide additional functions that 
modulate the adaptive immune response in the lung. These 
data highlight the critical role of pDCs in pulmonary viral in-
fection and these data may be of use in future studies for the 
development of new treatment strategies or novel vaccines 
for RSV infection.
MATERIALS AND METHODS
Animals. Female BALB/cByJ mice, 6–8 wk of age, were obtained from 
The Jackson Laboratory. All mice were housed under specifi  c pathogen-free 
conditions within the animal care facility at the University of Michigan. All 
experiments were approved by the University of Michigan Committee on 
the Use and Care of Animals.
RSV infection model and RSV plaque assay. RSV subtype A, Umich/
line 19 strain was derived from a clinical isolate at the University of   Michigan 
and was propagated in Hep2 cells. Infection was allowed to proceed   until 
  syncytia were observed. Cells were frozen at −80°C and the supernatant was 
Figure 4.  Role of IFN𝗂 during RSV infection in control and pDC-
depleted mice. (A) IFNα4 mRNA and IFNα protein was measured before 
and at different time points after RSV infection in homogenates of lungs 
of control (▲) or pDC-depleted (■) mice. Results are displayed as mean 
increase to control or pg/ml ± SEM. *, P < 0.05 compared with control 
mice, n = 5 mice per group. (B) On 6 dpi, RSV titers were determined 
in the lungs of control (cont), RSV-infected (RSV), IFNα-treated, RSV-
infected (RSV+IFNα), or DC-depleted, IFNα-treated, RSV-infected (RSV +
120G8+IFNα) mice by the plaque assay. Data are presented as mean 
PFU per gram lung ± SEM. In addition, RSV G protein RNA transcription 
in the lung on 6 dpi was measured by quantitative real-time PCR 
(Taqman). Data are represented as mean fold increase to RSV-infected 
mice ± SEM. *, P < 0.05 compared with control mice; #, P < 0.05 
  compared with RSV-infected mice, n = 5 mice per group. (C) Airway re-
sponses were measured in control (cont), RSV-infected (RSV), IFNα-
treated, RSV-infected (RSV+IFNα), or pDC-depleted, IFNα-treated, 
RSV-infected (RSV +120G8+IFNα) mice after one dose of methacholine 
and compared with basal measurements. Data are represented as mean 
airway resistance in cm H2O/ml/s ± SEM. *, P < 0.01 compared with 
noninfected control mice; #, P < 0.05 compared with RSV-infected mice, 
n = 5 mice per group. (D) Lung-draining lymph nodes were isolated 
from control (cont), RSV-infected (RSV), IFNα-treated, RSV-infected 
(RSV+IFNα), and pDC-depleted, IFNα-treated, RSV-infected (RSV +
120G8+IFNα) mice and stimulated with anti-CD3 at a concentration 
of 5 × 106 cells/ml. Supernatants were analyzed using ELISA. Data are 
represented as mean ng/ml ± SEM. *, P < 0.01 compared with nonin-
fected control mice; #, P < 0.05 compared with RSV infected mice, n = 4 
mice per group.1158  PLASMACYTOID DENDRITIC CELLS IN RSV INFECTION | Smit et al. 
harvested, clarifi  ed, and aliquoted. This RSV preparation was tested negative 
for both endotoxin and mycoplasma. To determine viral titers in culture su-
pernatants and lung homogenates, an immunoplaque assay was performed as 
described previously (25). For RSV infection, mice were anesthetized with 
ketamine/xylazine and intratracheally infected with  105 PFU of RSV. For 
determination of viral titers, lungs from RSV-infected mice were isolated on 
6 dpi followed by dispersion and analysis by RSV plaque assay. Administration 
of UV-irradiated RSV does not elicit any responses in the lungs in mice, dem-
onstrating no confounding eff  ects of the medium used to culture RSV in vivo.
Detection of DC subtypes in lung. Mice were infected with RSV and at 
1, 5, 7, 9, 14, 21, and 30 dpi, lungs and lung-draining mediastinal lymph 
nodes were isolated and dispersed using 0.2% collagenase (Type IV; Sigma-
Aldrich) in RPMI 1640 with 10% FCS at 37°C for 45 min. After lysis of red 
blood cells and blocking nonspecifi  c binding by FcR, cells were counted and 
stained with anti-mPDCA1–FITC (Miltenyi Biotec), 120G8-Alexa 488 
(AbCys S.A.) or anti-CD4–PerCp-Cy5.5, anti–DX-5–PE, anti–CD19-PE, 
anti–CD8-PE, anti–CD11c-PE, anti-CD11c–FITC, anti-B220–FITC, anti-
Gr-1–PE, anti-CD11b–FITC antibodies, or isotype controls (all antibodies 
were obtained from BD Biosciences). Cells were fi  xed with paraformalde-
hyde (1%, overnight) and kept in the dark at 4°C until analysis on a Cy-
tomics FC500 fl  ow cytometer (Beckman Coulter). Double positive cells 
were selected using single staining and isotype controls. Fixation of cells does 
not aff  ect analysis and number of cells recovered.
Depletion of pDCs and IFN𝗂 treatment in vivo. pDCs were depleted 
in vivo by i.p. injecting mice 1 d before and day 1 after RSV infection with 
150 μg 120G8 antibody (provided by Dr. P. Zavodny, Schering-Plough 
Research Institute, Kenilworth, NJ) as described previously (17, 26). All 
control and RSV-infected mice received an isotype control antibody (rat 
IgG; Sigma-Aldrich).
In a separate set of experiments, mice were treated i.t. with 104 IU mu-
rine recombinant IFNα (PBL Biomedical Laboratories) or with control dilu-
ent alongside the RSV infection as described previously (24).
Measurement of airway responsiveness. At day 9 after RSV infection, 
airway reactivity in anesthetized mice was measured as described previously 
(6). In brief, mice were anesthetized with sodium pentobarbital and the tra-
chea was cannulated and ventilated using a pump ventilator. After baseline 
measurements, mice were injected i.v. with 2.5 μg of methacholine (Sigma-
Aldrich) and the peak airway resistance was recorded.
Histological analysis. Lungs were lavaged via the tracheal tube with 
1 ml of PBS. Total cell numbers were obtained and diff  erential cell counts 
were performed by counting cells on cytocentrifuged preparations stained 
with Diff  quick. After obtaining the lung lavage, lungs were infl  ated and 
maintained in formalin for 24 h before being processed into paraffi   n us-
ing standard histological techniques. Lung tissue sections were stained with 
hematoxylin and eosin (H&E) for analysis of infl  ammatory cell accumu-
lation and alcian blue/periodic acid-Schiff   (PAS) for assessment of mucus 
production. To quantify the mucus production in the lung, PAS sections 
were randomized and examined and scored on a scale from 1 to 4, with 1 
representing no mucus cell content.
Lymph node restimulation. On 6 dpi, single cell suspensions of lung-
draining lymph nodes were prepared by isolation of mediastinal lymph 
nodes, pushing cells trough a nylon mesh using a syringe and lysis of red 
blood cells. Cells were cultured in RPMI 1640 medium (RPMI 1640 with 
10% FCS, l-glutamin and Pen/Strep) at a concentration of 5 × 106 cells/ml 
in the presence of either 10 μg/ml plate-bound anti-CD3 (BD Biosciences) 
or medium alone and incubated at 37°C. After 3 d, supernatants were col-
lected and stored at −80°C until further analysis.
ELISA and quantitative PCR analysis. Standardized sandwich ELISAs 
were performed to measure cytokine and chemokine levels in culture super-
natants as described previously (6). All antibody pairs were obtained from 
R&D Systems. IFNα was measured in lung homogenates using a commer-
cial ELISA kit obtained from PBL Biomedical Laboratories that has a detec-
tion limit of 13 pg/ml.
RNA was isolated from lungs using TRIzol reagent (Invitrogen), ac-
cording to the instructions of the manufacturer. Each sample was reverse 
transcribed into cDNA and analyzed by quantitative real-time PCR using 
Taqman (Applied Biosytems). Raw data were normalized to GAPDH con-
trol standards in each sample.
Statistical analysis. Signifi  cance was determined using one-way analysis of 
variance or single Student’s t tests with 95% confi  dence intervals. A p-value 
of <0.05 was considered signifi  cant.
Online supplemental material. Table S1 shows the effi   cacy of the 120G8 
antibody in depleting pDCs in the lung. The 120g8 antibody decreased the 
number of pDCs, but not the number of cDCs in the lung after RSV infec-
tion. Fig. S1 displays the analysis of CD11chigh/CD11bhigh, CD11c+/B220+, 
and CD11c+/mPDCA1+ DCs as enumerated in Fig. S1. Fig. S2 shows the 
quantifi  cation of the infl  ammation and mucus production in the lung as 
shown in Fig. S2 B. Shown are mucus scores from the PAS stained slides, the 
number of lymphocytes in the lung lavage fl  uid, and the expression of Gob5 
and Muc5ac mRNA in the lung. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20052359/DC1.
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